News & Updates

AI tools are being increasingly integrated into clinical practice, offering many advances in administration and patient care. However, as with any emerging technology, there are risks that practitioners should understand and manage. One such risk that clinicians should not overlook is consent, especially understanding how to navigate consent when using diagnostic support tools, ambient scribes or generative AI. Ensuring fully informed consent has been obtained, and can be withdrawn, is essential to maintaining trust and upholding professional and ethical standards. This article aims to provide a practical overview of the consent implications to consider when using AI in clinical practice.

Performing brief bouts of moderate-to-vigorous intensity exercise throughout the day reduces time spent in hyperglycaemia when compared with performing one cumulative exercise session or inactivity, as shown in a study.

In patients with suspected small bowel bleeding (SSBB), having a haemoglobin level of <8.0 g/dL appears to increase the risk of mortality, suggests a study.

Patients with maple syrup urine disease (MSUD) have lower levels of docosahexaenoic acid (DHA), resulting from inadequate dietary intake and change in n-3 polyunsaturated fatty acid (PUFA) metabolism, according to a study.

Use of proton pump inhibitors (PPIs) results in improvements in nighttime heartburn and reflux-related sleep disturbances, particularly in patients with reflux-driven nocturnal symptoms, a study has shown.

In the treatment of patients with Parkinson disease (PD), nicotinamide riboside does not appear to confer beneficial effects and is even associated with worse clinical outcomes compared with placebo, according to a phase III trial.

Treatment with tozorakimab as an add-on to inhaled maintenance therapy helps lessen the frequency of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations, and this benefit is observed in both former and current smokers.

Older patients with major depressive disorder (MDD) treated with active theta-burst stimulation (TBS) show no significantly greater reduction in Hamilton Depression Rating Scale (HAM-D) scores than those who received sham stimulation at week 6, according to a study.